Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: Comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T

Journal of Magnetic Resonance Imaging

Volumn 31, Issue 3, 2010, Pages 549-555

  Attenberger, Ulrike I ^a   Runge, Val M ^b   Morelli, John N ^b   Williams, Jonathan ^b   Jackson, Carney B ^c   Michaely, Henrik J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

1.5 T; 3 T; Brain tumor; Gadobutrol; Gadopentetate dimeglumine; Gadoterate meglumine

Indexed keywords

GADOBUTROL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTRAST NOISE RATIO; CONTROLLED STUDY; GLIOMA; INJECTION; MATHEMATICAL PARAMETERS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZATION; RAT; SIGNAL NOISE RATIO; STATISTICAL SIGNIFICANCE; TIME;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHELATING AGENTS; DISEASE MODELS, ANIMAL; GADOLINIUM DTPA; GLIOMA; HUMANS; IONS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; RATS; RATS, INBRED F344;

EID: 77649206972     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22089     Document Type: Article

References (26)

1. Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 2007;25:884-899.
2. Noebauer-Huhmann IM, Pinker K, Barth M, et al. Contrast-enhanced, high-resolution, susceptibility-weighted magnetic resonance imaging of the brain: dose-dependent optimization at 3 Tesla and 1.5 Tesla in healthy volunteers. Invest Radiol 2006;41: 249-255.
3. Ba-Ssalamah A, Nobauer-Huhmann IM, Pinker K, et al. Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases. Invest Radiol 2003;38:415-422.
4. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 2008;66:160-167.
5. Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29: 887-894.
6. Spinazzi A, Kirchin MA, Pirovano G. Nephrogenic systemic fibrosis: the need for accurate case reporting. J Magn Reson Imaging 2009;29:1240; author reply 1241.
7. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-576.
8. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 2007;80:581-582; author reply 584-585.
9. Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43: 817-828.
10. Kostler H, Ritter C, Lipp M, Beer M, Hahn D, Sandstede J. Comparison of different contrast agents and doses for quantitative MR myocardial perfusion imaging. J Magn Reson Imaging 2008; 28:382-389.
11. Attenberger UI, Michaely HJ, Wintersperger BJ, et al. Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: interindividual comparison of 0.2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at 3.0 T. Eur Radiol 2008;18:1260-1268.
12. Szucs-Farkas Z, Froehlich JM, Ulrich M, et al. 1.0-M gadobutrol versus 0.5-M gadoterate for peripheral magnetic resonance angiography: a prospective randomized controlled clinical trial. J Magn Reson Imaging 2008;27:1399-1405.
13. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213-221.
14. Wintersperger BJ, Runge VM, Biswas J, et al. Brain magnetic resonance imaging at 3 Tesla using BLADE compared with standard rectilinear data sampling. Invest Radiol 2006;41: 586-592.
15. Chang KH, Ra DG, Han MH, Cha SH, Kim HD, Han MC. Contrast enhancement of brain tumors at different MR field strengths: comparison of 0.5 T and 2.0 T. AJNR Am J Neuroradiol 1994;15: 1413-1419; discussion 1420-1423.
16. Biswas J, Nelson CB, Runge VM, et al. Brain tumor enhancement in magnetic resonance imaging: comparison of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) at 1.5 versus 3 Tesla. Invest Radiol 2005;40:792-797.
17. Nobauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V, et al. Magnetic resonance imaging contrast enhancement of brain tumors at 3 Tesla versus 1.5 Tesla. Invest Radiol 2002;37:114-119.
18. Akeson P, Vikhoff B, Stahlberg F, Holtas S. Brain lesion contrast in MR imaging. Dependence on field strength and concentration of gadodiamide injection in patients and phantoms. Acta Radiol 1997;38:14-18.
19. Haustein J, Laniado M, Niendorf HP, et al. Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: dosage and field strength. AJNR Am J Neuroradiol 1992; 13:1199-1206.
20. Frayne R, Goodyear BG, Dickhoff P, Lauzon ML, Sevick RJ. Magnetic resonance imaging at 3.0 Tesla: challenges and advantages in clinical neurological imaging. Invest Radiol 2003;38:385-402.
21. Lu H, Nagae-Poetscher LM, Golay X, Lin D, Pomper M, van Zijl PC. Routine clinical brain MRI sequences for use at 3.0 Tesla. J Magn Reson Imaging 2005;22:13-22.
22. Tweedle MF. The ProHance story: the making of a novel MRI contrast agent. Eur Radiol 1997;7(Suppl 5):225-230.
23. Idee JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88.
24. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008;66:175-179.
25. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008;66:230-234.
26. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008;43:65-75.